TSE:CRDL Cardiol Therapeutics 5/11/2026 Earnings Report C$1.81 -0.06 (-3.21%) As of 05/15/2026 04:00 PM Eastern ProfileEarnings History Cardiol Therapeutics EPS ResultsActual EPS-C$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACardiol Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACardiol Therapeutics Announcement DetailsQuarterDate5/11/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Cardiol Therapeutics Earnings HeadlinesHere's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn SituationMay 15 at 5:40 PM | finance.yahoo.comCardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash PositionMay 13 at 12:50 PM | theglobeandmail.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 16 at 1:00 AM | Behind the Markets (Ad)Cardiol Therapeutics (TSE:CRDL) Trading 1.1% Higher - Still a Buy?May 13 at 3:05 AM | americanbankingnews.comAnalysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before LongJanuary 12, 2026 | finance.yahoo.comHC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy RecommendationDecember 2, 2025 | msn.comSee More Cardiol Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email. Email Address About Cardiol TherapeuticsCardiol Therapeutics (TSE:CRDL) (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.View Cardiol Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early Innings Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
